Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Acute kidney injury (AKI) is characterized by a rapid decline in kidney function and is associated with significant morbidity and mortality. Nitric oxide (NO) and its endogenous inhibitor, asymmetric dimethylarginine (ADMA), play critical roles in renal physiology and pathophysiology. This study investigated the effects of haemodialysis on NO and ADMA levels in AKI patients. This case‐control study included 300 participants: 50 healthy controls and 250 AKI patients undergoing haemodialysis. AKI patients were categorized into five groups based on dialysis stage (before dialysis, after first, second, third and fourth dialysis). Plasma ADMA and NO concentrations were measured using ELISA. NO levels were significantly elevated in AKI patients compared to controls (p<0.0001) and showed dynamic changes across different dialysis stages, with the highest levels observed before dialysis. ADMA levels were also significantly elevated in AKI patients (p<0.0001) but did not show a consistent pattern of reduction during haemodialysis. Haemodialysis effectively reduces plasma NO concentrations in AKI patients, suggesting its potential utility in removing excess NO. However, ADMA clearance appears to be less efficient. The persistent elevation of ADMA despite haemodialysis may have implications for vascular health and kidney disease progression. Monitoring NO and ADMA levels during haemodialysis could provide valuable insights into treatment response and disease prognosis.
How to cite this article:
Nutan G. Ghadage, Subodhini Abhang and Ashok Vankudre. The Role of Nitric Oxide Synthase Inhibitor: ADMA in the Patients of Acute Kidney Injury Undergoing Haemodialysis.
DOI: https://doi.org/10.36478/10.36478/makrjms.2025.1.416.421
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2025.1.416.421